Results 21 to 30 of about 8,981 (169)

Paraoxonase 1 in Chronic Kidney Failure [PDF]

Journal of Lipids, 2012
In this review we summarize the findings from the literature and our own laboratory on the decreased PON1 activity in renal failure, the mechanisms proposed and the effect of interventions. In addition to profound alterations in lipoproteins, reduced serum PON1 activity has been clearly established in the past decade and could contribute to accelerated
Alejandro Gugliucci, Kazuhiko Kotani, Satoshi Kimura   +2 more
openaire   +2 more sources

Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis

Molecules, 2021
Oxidative stress is involved in the pathophysiology of nonalcoholic fatty liver disease (NAFLD). However, reliable biomarkers of NAFLD in relation to oxidative stress are not available.
Kazuhiko Kotani, Jun Watanabe, Kouichi Miura, Alejandro Gugliucci   +3 more
doaj   +1 more source

Study of Paraoxonase 1 (PON1) Activity as an Independent Risk Factor in Coronary Artery Disease [PDF]

National Journal of Laboratory Medicine, 2013
Background: Coronary Artery Disease is the major cause of mortality and morbidity worldwide. Human serum paraoxonase-1 is a high density lipoprotein bound enzyme exhibiting antiatherogenic properties.
Sangita M. Patil, Mangesh P. Banker, Ramchandra K. Padalkar, Abhijit P. Pathak, Shital Ghodke, Anjali S. Phatake , Sonali S. Bhagat, Rahul A. Ghone   +7 more
doaj   +1 more source

Study the levels of Leptin, and Adiponectin with Paraoxonase in Obese Individuals (male & female)

Tikrit Journal of Pure Science, 2023
Obesity is a well-known risk factor of metabolic complications and cardiovascular disease. Associations between anthropometric measurements and fat distribution and risk factors  for cardiovascular disease have been demonstrated in several populations.
Entedhar R. Sarhat
doaj   +1 more source

The Effects of Bioavailability-Enhanced Curcuminoids on Serum Paraoxonase-1 Activity in Patients with Metabolic Syndrome [PDF]

Journal of Cardio-Thoracic Medicine, 2021
Introduction: Metabolic syndrome (MetS) is characterised by a clustering of metabolic cardiovascular disease (CVD) risk factors that include: central obesity, impaired glucose metabolism, dyslipidaemia (hypertriglyceridemia, increased low-density ...
Atena Raee, Seyed Mohammad Reza Parizadeh, Behdokht Fathi Dizaji, Amirhosein Sahebkar, Seyed Isaac Hashemy, Maryam Saberi-Karimian, Majid Ghayour-Mobarhan, Alireza Pasdar   +7 more
doaj   +1 more source

Paraoxonase 1 as an important antiatherogenic agent

Journal of Education, Health and Sport, 2019
The inverse relationship between High Density Lipoproteins (HDL) level and risk of ischaemic heart disease was proved by many epidemiological studies. Although the main mechanism of antiatherogenic activity of HDL is a reverse transport of cholesterol ...
Ewa Lidia Krzewicka-Romaniuk, Dagna Agnieszka Siedlecka, Anna Warpas, Grażyna Wójcicka   +3 more
doaj   +3 more sources

Genetic polymorphisms of paraoxonase 1 and susceptibility to atherogenesis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2013
Introduction. Paraoxonase 1 (PON1) is a multifunctional enzyme associated with high-density lipoprotein particles (HDL). It is a cellular antioxidant that hydrolyses oxidized macromolecules, especially low-density lipoproteins (ox-LDL).
Grubiša Ivana, Otašević Petar, Dimković Nada, Nedeljković Ivana, Toljić Boško, Vučinić Nada   +5 more
doaj   +1 more source

Paraoxonase 1 status in the Thai population [PDF]

Journal of Human Genetics, 2005
Human serum paraoxonase 1 (PON1), a high-density lipoprotein (HDL)-associated enzyme, has been shown to reduce the oxidation of low-density lipoprotein (LDL) and HDL by degrading lipid peroxides. This property of PON1 accounts for its ability to protect against atherosclerosis.
Wimon, Phuntuwate, Chuthamanee, Suthisisang, Banhan, Koanantakul, Michael I, Mackness, Bharti, Mackness   +4 more
openaire   +2 more sources

Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates [PDF]

Molecules, 2020
Mammalian paraoxonase-1 hydrolyses a very broad spectrum of esters such as certain drugs and xenobiotics. The aim of this study was to determine whether carbamates influence the activity of recombinant PON1 (rePON1). Carbamates were selected having a variety of applications: bambuterol and physostigmine are drugs, carbofuran is used as a pesticide ...
Anita Bosak, Aljoša Bavec, Tilen Konte, Goran Šinko, Zrinka Kovarik, Marko Goličnik   +5 more
openaire   +5 more sources

Serum paraoxonase 1 (PON1) measurement: an update [PDF]

BMC Veterinary Research, 2014
Paraoxonase 1 (PON1) is a widely studied enzyme based on its protective role against poisoning by organophosphate (OP) metabolites of specific OP insecticides and in vascular disease, as well as its use as biomarker of diseases involving oxidative stress, inflammation and liver diseases.This review provides an update about the current knowledge in the ...
Ceron, Jose J, Tecles, Fernando, Tvarijonaviciute, Asta   +2 more
openaire   +2 more sources